dr donna h ryan glp 1 Today is World Obesity Day.🌎, According to @worldobesity, over billion people worldwide are living with obesity, and projections show that 4 billion people are expected to be living with overweight Prof. Donna H. Ryan |

We expect that law firms with a large volume of Ozempic cases will file some in state court as a way to hedge their bets against putting all their cases into one litigation, in front of one judge

In 2024, it repositioned its product line to cater to people taking GLP-1 drugs for weight loss, hoping to attract customers and grow its business

Innovation requires courage and responsibility moving beyond fear-based restrictions and into structured, supervised research and care

The frequency of menstrual changes in placebo groups was lower but not zero, confirming that some disruption stems from weight reduction rather than the drug itself

A decelerating trajectory is biologically plausible, but without multi-year empirical data we cannot be certain which projection most closely reflects long term real-world outcomes. But she added: Overall, the study reinforces that GLP-1 receptor agonists are unlikely to produce durable weight loss if used as short term interventions without longer term management plans